All In Biotech

Free tool

FAERS Monitor: Urso 250

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020675 or its brand name (Urso 250, Ursodiol). Reports on generic versions are filed under their own applications.

Reports

22,309

Serious

17,866

80% of reports

Hospitalization

10,186

Death reported

3,055

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use1,842
  • pruritus1,326
  • diarrhoea1,284
  • fatigue1,129
  • nausea1,091
  • pyrexia1,016
  • drug ineffective987
  • pneumonia791
  • death730
  • vomiting714
  • headache647
  • dyspnoea609
  • rash577
  • abdominal pain565
  • decreased appetite557

Reports by year received

View as table
YearReports
200440
2005180
2006110
2007277
2008418
2009486
2010641
2011908
2012810
2013226
2014280
2015428
2016585
2017908
20181,402
20191,264
20201,328
20211,584
20222,209
20232,018
20242,081
20252,369
20261,757

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,031,850 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pruritusSignal1,3263.33.12,108
pyrexiaSignal1,0162.82.61,166
pneumoniaSignal7912.32.2592
abdominal painSignal5652.32.1414
decreased appetiteSignal5572.32.1395
off label use1,8422.01.9937
diarrhoea1,2841.91.8541
vomiting7141.41.395
fatigue1,1291.41.3115
nausea1,0911.31.278
rash5771.21.229
dyspnoea6091.00.90
headache6471.00.90
death7300.80.738
drug ineffective9870.70.7129

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.